Biogen appoints ex-Sinofi boss Christopher Viehbacher as its next CEO. Here are the details

18 patients took a drug called Dostarlimab for around six months in a small clinical trial conducted by the Memorial Sloan Kettering Cancer Center. In the end, every one of them saw their tumours disappear, New York Times reported.

Dostarlimab is a drug with laboratory-produced molecules and it acts as substitute antibodies in the human body. The patients underwent a series of medical exams -- physical, endoscopy, bioscopy, PET scans and MRI scans -- and none of the reports showed a tumour.

Patients involved in the clinical trial earlier underwent treatments such as chemotherapy, radiation, and invasive surgery that could result in bowel, urinary, and even sexual dysfunction. They then went into the trial expecting to have to go through these procedures as the next step. However, to their surprise, no further treatment was needed.

The findings of this trial have shocked experts and they have pointed out that complete remission in every single patient is "unheard-of". Dr Alan P. Venook, who is a colorectal cancer specialist at the University of California, hailed the research as "world-first". Not all of the patients suffered significant complications from the drug trial.

An Indian origin patient was among those who had the "miracle" cure. "It's a miracle", Nisha Varughese said about the immunotherapy drug's efficacy in curing her.